China Heal Plus

HEALTHCARE UPDATE

FDA Lists Traditional Approval for Keytruda’s TMB-High Cancer Indication

By China Heal Plus · Updated

An FDA oncology listing now records traditional approval for a specific use of pembrolizumab, marketed as Keytruda, in cancers with high tumor mutational burden. The listed date is October 16, 2026.

A Change in US Regulatory Status

The FDA table traces this indication from accelerated approval on June 16, 2020 to traditional approval on October 16, 2026. Its description covers adults and children whose TMB-high cancers cannot be removed surgically or have spread, have worsened after earlier treatment, and have no satisfactory alternatives. An FDA-approved test must establish the biomarker.

Tumor mutational burden describes the number of genetic changes measured in a tumor. This update concerns a particular indication; it does not make every cancer patient eligible or establish access or insurance coverage outside the United States.

Sources: [1], [2]

Records for a Specialist Review

A second-opinion request about this indication can identify the molecular test used, the cancer diagnosis and earlier treatments in its records summary. The reviewing specialist assesses the case and the treatment options available locally.

Sources and data notes

  1. FDA: cancer indications converted to traditional approval

    Original table checked October 19, 2026. The Keytruda TMB-high row lists traditional approval October 16, 2026 and accelerated approval June 16, 2020. The page publication date and the underlying new approval letter were not independently established.

  2. FDA: original 2020 pembrolizumab TMB-high announcement

    June 16, 2020 accelerated-approval background, not a new 2026 announcement. Original checked October 19, 2026. Record-preparation wording is our editorial interpretation; no individual treatment recommendation.

Published by China Heal Plus. General information, not an individual medical assessment. Inclusion of a hospital or physician does not imply a partnership or endorsement of our service.

All healthcare updates